Affordable Access

Publisher Website

Efficacy and safety of a multiherbal formula with vitamin C and zinc (Immumax) in the management of the common cold

International Journal of General Medicine
Dove Medical Press
Publication Date
DOI: 10.2147/ijgm.s16266
  • Original Research
  • Design


Objective To study the potential efficacy and tolerability of a natural multiherbal formula (Immumax) containing Echinacea extract 120 mg, garlic powder 100 mg, Nigella sativa oil 200 mg, and Panax ginseng extract 50 mg plus vitamin C 50 mg and elemental zinc 7.5 mg in the treatment of patients suffering from the common cold. Design and setting The study was conducted in a prospective, double-blind, randomized, controlled study design in an outpatient setting. Patients and methods Sixty-two eligible patients with symptoms of the common cold were randomized to either Immumax or placebo treatment groups for the duration of their symptoms or a maximum of 14 days. Resolution rates were estimated using Kaplan–Meier analysis, and resolution profiles were compared between groups using the log-rank test. The mean percentage change in total symptom severity scores at days 4 and 8 from baseline were compared between the two groups by one-way analysis of variance (ANOVA). Results The median (interquartile range) time to resolution of all symptoms was 8 (5–9) days in the placebo group and 4 (3–6) days in the Immumax group. The results of the log-rank test indicate that symptoms resolved significantly faster in the Immumax group than in the placebo group (P < 0.001). The mean percentage reduction in total symptom severity scores from baseline at days 4 and 8 was significantly greater in the Immumax group than in the placebo group by one-way ANOVA (P < 0.01). Conclusion We can conclude from our study that Immumax is helpful in reducing the duration and severity of common cold symptoms.

There are no comments yet on this publication. Be the first to share your thoughts.